Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia

Aryan N. Mooss, Syed M. Mohiuddin, Tom T. Hee, Dennis J. Esterbrooks, Daniel E. Hilleman, Karen S. Rovang, Michael H. Sketch

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

High-dose intravenous amiodarone was given to 35 patients with recurrent life-threatening ventricular tachycardia (VT) refractory to conventional anti-arrhythmic agents. Intravenous amiodarone was given as a 5 mg/kg dose over 30 minutes followed by 20 to 30 mg/kg/day as a constant infusion for 5 days. Twenty-two (63%) patients responded to intravenous amiodarone. All 22 responders received oral amiodarone. Thirteen (59%) continue to receive oral amiodarone after an average follow-up of 19 months, 4 (18%) had sudden cardiac death on oral amiodarone, 2 (9%) died while receiving amiodarone, secondary to left ventricular failure, and 3 (14%) discontinued amiodarone because of side effects. Of the 13 (37%) nonresponders, 10 died in the hospital while receiving intravenous amiodarone, secondary to lethal arrhythmia. Three nonresponders were discharged from the hospital; 2 with automatic cardioverter/defibrillators and 1 receiving a combination of antiarrhythmic agents. Serious adverse events occurred in 13 (37%) patients during intravenous amiodarone therapy. These included hypotension in 8 patients, symptomatic bradycardia in 4 patients and sinus arrest with bradycardia and hypotension in 1 patient. Minor side effects occurred in 23 (66%) patients. In conclusion, high dose intravenous amiodarone is effective in most patients with recurrent, sustained VT but is associated with an unacceptably high incidence of serious adverse events. The optimal dose and duration of intravenous amiodarone for patients with recurrent, refractory sustained VT remain unknown.

Original languageEnglish
Pages (from-to)609-614
Number of pages6
JournalAmerican Journal of Cardiology
Volume65
Issue number9
DOIs
StatePublished - Mar 1 1990

Fingerprint

Amiodarone
Ventricular Tachycardia
Bradycardia
Hypotension
Defibrillators
Anti-Arrhythmia Agents
Sudden Cardiac Death
Cardiac Arrhythmias

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. / Mooss, Aryan N.; Mohiuddin, Syed M.; Hee, Tom T.; Esterbrooks, Dennis J.; Hilleman, Daniel E.; Rovang, Karen S.; Sketch, Michael H.

In: American Journal of Cardiology, Vol. 65, No. 9, 01.03.1990, p. 609-614.

Research output: Contribution to journalArticle

@article{53f7d689e0d2494a917026420439fbe2,
title = "Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia",
abstract = "High-dose intravenous amiodarone was given to 35 patients with recurrent life-threatening ventricular tachycardia (VT) refractory to conventional anti-arrhythmic agents. Intravenous amiodarone was given as a 5 mg/kg dose over 30 minutes followed by 20 to 30 mg/kg/day as a constant infusion for 5 days. Twenty-two (63{\%}) patients responded to intravenous amiodarone. All 22 responders received oral amiodarone. Thirteen (59{\%}) continue to receive oral amiodarone after an average follow-up of 19 months, 4 (18{\%}) had sudden cardiac death on oral amiodarone, 2 (9{\%}) died while receiving amiodarone, secondary to left ventricular failure, and 3 (14{\%}) discontinued amiodarone because of side effects. Of the 13 (37{\%}) nonresponders, 10 died in the hospital while receiving intravenous amiodarone, secondary to lethal arrhythmia. Three nonresponders were discharged from the hospital; 2 with automatic cardioverter/defibrillators and 1 receiving a combination of antiarrhythmic agents. Serious adverse events occurred in 13 (37{\%}) patients during intravenous amiodarone therapy. These included hypotension in 8 patients, symptomatic bradycardia in 4 patients and sinus arrest with bradycardia and hypotension in 1 patient. Minor side effects occurred in 23 (66{\%}) patients. In conclusion, high dose intravenous amiodarone is effective in most patients with recurrent, sustained VT but is associated with an unacceptably high incidence of serious adverse events. The optimal dose and duration of intravenous amiodarone for patients with recurrent, refractory sustained VT remain unknown.",
author = "Mooss, {Aryan N.} and Mohiuddin, {Syed M.} and Hee, {Tom T.} and Esterbrooks, {Dennis J.} and Hilleman, {Daniel E.} and Rovang, {Karen S.} and Sketch, {Michael H.}",
year = "1990",
month = "3",
day = "1",
doi = "10.1016/0002-9149(90)91039-9",
language = "English",
volume = "65",
pages = "609--614",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia

AU - Mooss, Aryan N.

AU - Mohiuddin, Syed M.

AU - Hee, Tom T.

AU - Esterbrooks, Dennis J.

AU - Hilleman, Daniel E.

AU - Rovang, Karen S.

AU - Sketch, Michael H.

PY - 1990/3/1

Y1 - 1990/3/1

N2 - High-dose intravenous amiodarone was given to 35 patients with recurrent life-threatening ventricular tachycardia (VT) refractory to conventional anti-arrhythmic agents. Intravenous amiodarone was given as a 5 mg/kg dose over 30 minutes followed by 20 to 30 mg/kg/day as a constant infusion for 5 days. Twenty-two (63%) patients responded to intravenous amiodarone. All 22 responders received oral amiodarone. Thirteen (59%) continue to receive oral amiodarone after an average follow-up of 19 months, 4 (18%) had sudden cardiac death on oral amiodarone, 2 (9%) died while receiving amiodarone, secondary to left ventricular failure, and 3 (14%) discontinued amiodarone because of side effects. Of the 13 (37%) nonresponders, 10 died in the hospital while receiving intravenous amiodarone, secondary to lethal arrhythmia. Three nonresponders were discharged from the hospital; 2 with automatic cardioverter/defibrillators and 1 receiving a combination of antiarrhythmic agents. Serious adverse events occurred in 13 (37%) patients during intravenous amiodarone therapy. These included hypotension in 8 patients, symptomatic bradycardia in 4 patients and sinus arrest with bradycardia and hypotension in 1 patient. Minor side effects occurred in 23 (66%) patients. In conclusion, high dose intravenous amiodarone is effective in most patients with recurrent, sustained VT but is associated with an unacceptably high incidence of serious adverse events. The optimal dose and duration of intravenous amiodarone for patients with recurrent, refractory sustained VT remain unknown.

AB - High-dose intravenous amiodarone was given to 35 patients with recurrent life-threatening ventricular tachycardia (VT) refractory to conventional anti-arrhythmic agents. Intravenous amiodarone was given as a 5 mg/kg dose over 30 minutes followed by 20 to 30 mg/kg/day as a constant infusion for 5 days. Twenty-two (63%) patients responded to intravenous amiodarone. All 22 responders received oral amiodarone. Thirteen (59%) continue to receive oral amiodarone after an average follow-up of 19 months, 4 (18%) had sudden cardiac death on oral amiodarone, 2 (9%) died while receiving amiodarone, secondary to left ventricular failure, and 3 (14%) discontinued amiodarone because of side effects. Of the 13 (37%) nonresponders, 10 died in the hospital while receiving intravenous amiodarone, secondary to lethal arrhythmia. Three nonresponders were discharged from the hospital; 2 with automatic cardioverter/defibrillators and 1 receiving a combination of antiarrhythmic agents. Serious adverse events occurred in 13 (37%) patients during intravenous amiodarone therapy. These included hypotension in 8 patients, symptomatic bradycardia in 4 patients and sinus arrest with bradycardia and hypotension in 1 patient. Minor side effects occurred in 23 (66%) patients. In conclusion, high dose intravenous amiodarone is effective in most patients with recurrent, sustained VT but is associated with an unacceptably high incidence of serious adverse events. The optimal dose and duration of intravenous amiodarone for patients with recurrent, refractory sustained VT remain unknown.

UR - http://www.scopus.com/inward/record.url?scp=0025275131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025275131&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)91039-9

DO - 10.1016/0002-9149(90)91039-9

M3 - Article

VL - 65

SP - 609

EP - 614

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -